Menu Search
Equities

Lifecore Biomedical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LDE:DUS

Lifecore Biomedical Inc

Actions
  • Price (EUR)6.20
  • Today's Change-0.150 / -2.36%
  • Shares traded--
  • 1 Year change+6.90%
  • Beta0.6201
Data delayed at least 15 minutes, as of Feb 06 2026 18:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2007
  • Employees406.00
  • Location
    Lifecore Biomedical Inc3515 Lyman BoulevardCHASKA 55318United StatesUSA
  • Phone+1 (952) 368-4300
  • Fax+1 (302) 636-5454
  • Websitehttps://www.lifecore.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.